values, providing a favorable starting point for further development. Overall, KVAs emerge as stable, potent CatL inhibitors and a promising platform for selectivity and in cellulo optimization.
No takes yet. Share an insight, caveat, or question.
Fernández-de-la-Pradilla et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: